Blis Technologies
|
|
Blis Technologies (http://www.blis.co.nz) (NZX:BLT (http://www.nzx.com/market/security_details/by_security?code=BLT)) is a publicly listed New Zealand biotechnology company, formed in 2000 to commercialize bacteriocin-like inhibitory substances (BLIS), a class of peptides or proteins that prevent or control the growth of undesirable bacteria. The company is focussed on natural bacteriotherapy products to promote throat health and fresh breath.
In 2004 the company entered into a distribution agreements with the US distributor Therabreath (http://www.therabreath.com). The North American product, marketed as AKTIV-K12, is a mouthwash formulation containing Streptococcus Salivarius K12 that targets chronic bad breath sufferers.
Blis Technologies has also entered a further distribution agreement for its "Streptococcus Salivarius K12" bad breath solution, with an Australian distributor and dentist BreezeCare (http://www.breezecare.com.au). The BreezeCare product is marketed as KForce Clean Mouthwash (http://www.breezecare.com.au/aus/badbreathstarter.html). BreezeCare is further participating with Blis Technologies to help perfect other products slated for market release in the near future.
Blis Technologies has a small, but enthusiastic, following within the New Zealand investment community and the latest news, gossip and discussion can be found on the New Zealand based sharetrader website (http://www.sharetrader.co.nz/topic.asp?TOPIC_ID=16457).